阿替利珠单抗(Atezolizumab) - 药物靶点：PDL1_在研适应症：错配修复缺陷或微高卫星不稳定性结肠癌，结外NK-T细胞淋巴瘤，晚期非小细胞肺癌_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Anti-PDL-1-Genentech/Roche、Atezolizumab (Genetical Recombination)、Atezolizumab (genetical recombination) (JAN)

+ [11]

靶点

PDL1

作用方式

抑制剂

作用机制

PDL1抑制剂(程序性死亡配体1抑制剂)

治疗领域

肿瘤免疫系统疾病消化系统疾病+ [12]

在研适应症

错配修复缺陷或微高卫星不稳定性结肠癌结外NK-T细胞淋巴瘤晚期非小细胞肺癌+ [170]

非在研适应症

大肠腺癌晚期胆管癌晚期胆道癌+ [101]

原研机构

Genentech, Inc.

Universitair Medisch Centrum Groningen

在研机构

Hoffmann-La Roche, Inc.

罗氏（中国）投资有限公司

Roche Diagnostics GmbH

+ [20]

非在研机构

Sanofi

Kymab Ltd.

Pfizer Inc.

+ [15]

权益机构

NeoImmuneTech, Inc.

Harpoon Therapeutics, Inc.Novocure, Inc.

+ [26]

最高研发阶段批准上市

首次获批日期

美国 (2016-05-18),

尿路上皮癌

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (日本)、孤儿药 (澳大利亚)、优先审评 (澳大利亚)、附条件批准 (中国)、优先审评 (中国)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

Sequence Code 122091L

来源: *****

Sequence Code 4720027H

来源: *****

关联

933

项与阿替利珠单抗相关的临床试验

NCT07388524

/ Recruiting临床3期IIT

Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach.

开始日期2027-03-02

申办/合作机构

National Cancer Institute

NCT07170592

/ Not yet recruiting临床1期

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Combination With Hydroxyurea or Hydroxyurea/Atezolizumab in Treatment-refractory Solid Tumor Patients

This clinical trial aims to determine whether the administration of the investigational drug OTS-412, OTS-412 in combination with hydroxyurea or hydroxyurea/atezolizumab is safe and effective for patients with various types of cancer.

开始日期2027-01-01

申办/合作机构

Bionoxx, Inc.

NCT07796100

/ Not yet recruiting临床3期

A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-drug Conjugate (ADC) in Combination With a Checkpoint Inhibitor Compared to Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of ZL-1310 in combination with a checkpoint inhibitor compared to standard first-line therapy in participants with Extensive-Stage Small Cell Lung Cancer.

开始日期2026-12-31

申办/合作机构

再鼎医药（上海）有限公司

[+1]

100 项与阿替利珠单抗相关的临床结果

登录后查看更多信息

100 项与阿替利珠单抗相关的转化医学

登录后查看更多信息

100 项与阿替利珠单抗相关的专利（医药）

登录后查看更多信息

4,471

项与阿替利珠单抗相关的文献（医药）

2027-01-01·WATER RESEARCH

A scalable Zn-Mn-enabled catalytic ozonation process for robust drinking water purification

Article

作者: Hou, Congyu ; Zhang, Xihui ; Yang, Yulong ; Wang, Yanyi ; Zhang, Jiahui ; Deng, Yuepeng ; Tang, Shengyin ; Tang, Tianhao

In this study, a highly active oxygen-vacancy-rich Zn-Mn oxide catalyst (ZnMnO₃) and its kilogram-scalable form (ZnMn@CMs) were synthesized via a simple co-precipitation method for catalytic ozonation of drinking water, targeting enhanced removal of assimilable organic carbon precursors (AOC‑P) and trace emerging contaminants (ECs). Catalytic performance was evaluated using atrazine (ATZ) degradation as a model reaction, together with AOC-P and trace ECs removal under low O₃ dosages in real drinking water. The catalytic mechanism was elucidated through material characterization, oxygen vacancies (OVs) and reactive oxygen species (ROS) identification, Zn-Mn synergistic effects, and Fourier transform ion cyclotron resonance mass spectrometry analysis of ROS-dissolved organic matter interactions. Results demonstrated that OVs integrate Zn-Mn dual active sites and promote interfacial electron transfer, enhancing the exposure of hydrated hydroxyl groups at Zn sites and the adsorption of O₃ at Mn sites. Meanwhile, OVs could also be served as electron donors to activate O₂ for H₂O₂ generation, strengthening ROS transformation. Therefore, ZnMnO₃ with abundant OVs exhibited superior ozonation performance, achieving 96.71% ATZ degradation and a 7.80-fold rate enhancement over sole ozonation, along with excellent anion tolerance and cycling stability. In real drinking water treatment, the synergistic action of multiple ROS enables the O₃/ZnMn@CMs process to achieve outstanding removal efficiency for AOC-P (>90%), fluorescent components (>60%) and trace pharmaceuticals and personal care products (>66%), while maintaining excellent long-term catalytic stability (≥20 days) and low metal leaching. The scalable, oxygen-vacancy-rich Zn-Mn oxide catalyst developed herein provides an effective strategy for safeguarding high‑quality drinking water.

2027-01-01·WATER RESEARCH

Ultrafast micropollutant degradation via reductive activation of periodate under VUV/UV (185/254 nm) irradiation beyond photolysis

Article

作者: Ma, Jiayi ; Yang, Tao ; Lu, Haonan ; Zhang, Wenjun ; Luan, Tiangang ; Lu, Qiuling ; Wang, Kai ; Li, Ping ; Xu, Ying

The VUV/UV (185/254 nm)-activated periodate (PI)-based advanced oxidation process (AOP) showed superior efficacy for micropollutant removal, achieving nearly 100% degradation of atrazine (ATZ) and naproxen (NAP) within 90 s with 100 μM PI at pH 7.0. The ultrafast micropollutant degradation in VUV/UV/PI AOP was attributed to the enhanced generation of reactive species via synergistic activation of PI. Specifically, water was cracked by VUV into hydrogen atom radical (H^•) and/or hydrated electron (e_aq^-), while PI underwent VUV/UV photolysis and reductive activation by H•/e_aq^- to produce hydroxyl radical (HO^•) and ozone (O₃). Scavenging and probing experiments demonstrated the critical route for PI activation by H•/e_aq^-. Meanwhile, HO^• was the dominant reactive species and contributed 85.4% and 82.3% to ATZ and NAP degradation, while O₃ played a minor role with contributions of 0.04% and 9.7%, respectively. Iodate was the predominant product of PI decomposition with yield of 90.0% at 100 μM PI, pH 7.0 and 90 s. Increasing PI concentration (25-300 μM) accelerated the degradation of ATZ and NAP due to the stronger photons absorption and enhanced generation of reactive species. Faster ATZ and NAP degradation were observed at acidic pH (4.0-9.0) because protonated and monomeric form of PI were readily activated by photons and H•/e_aq^-. The existence of Cl^-, HCO₃^- and HA caused light shielding and HO^• scavenging effects, impeding the degradation of ATZ and NAP. These findings underlined the importance of reductive species for PI photochemical activation under VUV/UV irradiation.

2027-01-01·Annals of Hepatology

Real-world hepatocellular carcinoma management and guideline adherence in the Netherlands: A 5-year multicentre prospective cohort study

Article

作者: Braak, Jeffrey P B M ; de Bruijne, Joep ; Burgmans, Mark C ; de Vos-Geelen, Judith ; Wiese, Kevin ; de Wilde, Roeland F ; Verhagen, Coosje A M ; den Hoed, Caroline M ; Kramer, Matthijs ; Hoogwater, Frederik J H ; Coenraad, Minneke J ; Klümpen, Heinz-Josef ; Grossouw, Jochem M ; van der Helm, Danny ; van der Meeren, Pam E ; Koerkamp, Bas Groot ; Nijkamp, Maarten W ; Rousian, Merve ; Polak, Wojciech G ; van Delden, Otto M ; Takkenberg, R Bart ; Ruiter, Simeon J S

INTRODUCTION AND OBJECTIVES:

Dutch guidelines for hepatocellular carcinoma (HCC) are based on the European Association for the Study of the Liver (EASL) guideline. With the emergence of novel therapies, this study aimed to describe real-world first-line treatment practices in the Netherlands and assess their alignment with the EASL 2018 and 2025 recommendations.

PATIENTS AND METHODS:

Between 2019 and 2024, treatment-naive patients with HCC were prospectively enrolled across six Dutch tertiary referral centres as part of a cohort study paired with a biobank. Staging was in accordance with the Barcelona Clinic Liver Cancer (BCLC) 2022 classification.

RESULTS:

A total of 619 patients (79% male; median age 71 years) were included. Cirrhosis was registered in 65%. BCLC stage distribution was 11% BCLC-0, 53% BCLC-A, 14% BCLC-B, 18% BCLC-C, 2.9% BCLC-D, and 1.1% missing data. First-line therapy was most commonly thermal ablation (TA) in BCLC-0/A (48%), transarterial chemoembolization (TACE) in BCLC-B (46%), and systemic therapy in BCLC-C (41%). Adherence to first-line treatment recommendations was 46% per EASL 2018 and 63% per EASL 2025 guidelines. TACE, transarterial radioembolization and atezolizumab + bevacizumab were applied across all stages, ahead of guideline integration. One-year overall survival was 97% (BCLC-0), 91% (BCLC-A), 79% (BCLC-B), 70% (BCLC-C), and 33% (BCLC-D).

CONCLUSIONS:

Treatment practices in the Netherlands adapt in response to emerging evidence. Guideline-adherent first-line treatment was observed in 46% of patients according to the EASL 2018 guidelines and 63% according to the EASL 2025 guidelines. Although guidelines remain the foundational framework for clinical decision-making, treatment decisions in real-world practice often extend beyond guideline recommendations.

4,139

项与阿替利珠单抗相关的新闻（医药）

2026-10-23

·生物制品圈

ESMO 2026首日：29项LBA里的中国药

马德里时间今天上午，ESMO 2026开幕 10月23日，西班牙马德里IFEMA，2026年欧洲肿瘤内科学会（ESMO）年会正式开幕。会期五天，到10月27日结束。今年大会一共收录96项突破性摘要（LBA），其中12项进入最高规格的主席研讨会（Presidential Symposium）。中国药企相关的LBA有29项，占比刚过三成。主席研讨会上，中国原研药占了5个席位。这个数字放在五年前，很难想象。这29项里，15项是ADC，20项是III期临床。换句话说，中国创新药在ESMO舞台上拿出来的，不是早期探索数据，而是III期注册研究的顶线结果。 01 主席研讨会5席，都是什么药 12项主席研讨会LBA，中国占5席。逐一看： LBA6｜和黄医药赛沃替尼+奥希替尼（SAFFRON研究）适应症是奥希替尼耐药后、MET过表达/扩增的EGFR突变非小细胞肺癌。8月17日公布的顶线数据显示，联合疗法对比含铂双药化疗，PFS和OS均达统计学显著。阿斯利康已基于这项研究向FDA提交NDA。这是MET靶点在三代EGFR-TKI耐药后人群中，首个全球III期阳性结果，也是全口服无化疗方案。 LBA7｜康诺亚/乐普生物 CMG901（CLDN18.2 ADC）二线及以上CLDN18.2阳性胃/胃食管腺癌。7月底公布顶线，OS显著改善且临床意义重大。这是全球首个OS阳性的抗CLDN18.2 ADC III期。这款药由阿斯利康负责全球开发，康诺亚与乐普生物共同研发。 LBA8｜康方生物依沃西+化疗（HARMONi-GI1研究）一线晚期胆道癌，对照组是度伐利尤单抗+化疗。8月25日公布顶线，OS统计学显著阳性。依沃西是PD-1×VEGF双抗，这是它在胆道癌领域首次拿下III期OS阳性。Summit Therapeutics负责海外权益。 LBA9｜翰森制药 HS-20093（B7-H3 ADC，Ris-Rez）二线后复发难治骨肉瘤，对照组是吉西他滨+多西他赛。7月28日公布顶线，IRC评估PFS达到主要终点。这是近十年这个瘤种的首个阳性III期。GSK负责大中华区外权益，NDA已获CDE受理。 LBA11｜科伦博泰 sac-TMT（TROP2 ADC）经治晚期/复发子宫内膜癌。5月18日公布，OS和PFS双主要终点均达成。默沙东牵头全球开发，中国权益在科伦博泰。这是首个在该适应症中同时证明OS和PFS获益的ADC。 5项主席研讨会，全部是III期，全部在会前已经公布了顶线阳性结果。ESMO大会本身要读出具体的HR和中位数数据。 02 ADC占了半壁江山 29项LBA里，ADC有15项，超过一半。其中3项是双抗ADC：百利天恒的BL-B01D1（EGFR×HER3双抗ADC）占了两项——一项乳腺癌（LBA50），一项三代EGFR-TKI耐药后NSCLC（LBA71）；正大天晴的TQB2102（HER2双表位ADC）是第三项。 TROP2 ADC是出现频次最高的靶点：科伦博泰的sac-TMT有3项LBA——子宫内膜癌（LBA11）、PD-L1阴性非鳞NSCLC（LBA66）、EGFR-TKI耐药后NSCLC（LBA67）。 B7-H3 ADC也有3项：翰森HS-20093（骨肉瘤LBA9）、宜联生物YL201（鼻咽癌LBA43）、映恩生物DB-1311（铂耐药卵巢癌，壁报）。 HER2 ADC至少4项：恒瑞SHR-A1811（HER2低表达乳腺癌LBA13）、正大天晴TQB2102（HER2低表达乳腺癌LBA27）、荣昌生物RC48（乳房外Paget病LBA61）。另外，石药/康宁杰瑞的HER2双抗KN026在乳腺癌（LBA15）和胃癌（LBA80）各有一项。 CLDN18.2 ADC有两项：康诺亚CMG901（主席研讨会LBA7）和信达生物IBI343（胃/胃食管腺癌LBA77，武田合作）。一个明显的趋势：中国ADC的靶点覆盖面已经从HER2/TROP2扩展到B7-H3、B7-H4、CLDN18.2、Nectin-4、c-Met等新兴靶点，而且多个资产已经走到全球III期。图｜29项LBA靶点分布或ADC占比示意图03 几家重点企业的数字恒瑞医药这次拿了64项研究入选：3项Proffered Paper、3项Rapid Oral、32项壁报、26项电子壁报，创公司纪录。9月底前瞻口径还是"70余项"，最终以10月20日的64项为准。LBA层面，恒瑞有HER2 ADC SHR-A1811（乳腺癌LBA13）和HER3 ADC SHR-A2009（NSCLC LBA72）两项。石药集团8项入选，其中2项LBA——都是与康宁杰瑞共研的HER2双抗KN026（乳腺癌LBA15、胃癌LBA80）。1项优选口头、3项快速口头、3项壁报、1项电子壁报。百济神州（已更名BeOne Medicines）11项报告，核心亮点是泽尼达妥单抗+替雷利珠联合化疗一线HER2阳性胃食管腺癌的HERIZON-GEA-01第二次期中分析（LBA79），今天上午已报告。另有替雷利珠单抗系列的多项探索性分析。复宏汉霖斯鲁利单抗10项研究入选。美国桥接研究ASTRIDE将在10月26日首次口头报告。根据公司公开摘要，201例美国ES-SCLC患者中，斯鲁利单抗组中位OS为12.4个月，对照组阿替利珠单抗组为10.2个月；24个月OS率分别为32.2%和17.6%。作为头对头桥接研究，这个数据为斯鲁利单抗在美国的注册提供了支持。百利天恒的BL-B01D1（EGFR×HER3双抗ADC）有两项III期LBA：HR+/HER2-乳腺癌（LBA50）和三代EGFR-TKI耐药后NSCLC（LBA71），均与BMS合作开发。信达生物的CLDN18.2 ADC（IBI343/TAK-921）有一项III期LBA（LBA77，武田合作），国内NDA已获优先审评。04 接下来四天，看什么大会从10月23日持续到27日，LBA详细数据会在会期内陆续读出。几个关键时间点： 10月24日（周五）：翰森HS-20089（B7-H4 ADC，铂耐药卵巢癌）更长随访更新；康宁杰瑞JSKN033宫颈癌数据快速口头报告。 10月25日（周六）：和黄SAFFRON主席研讨会（LBA6）；康方HARMONi-GI1主席研讨会（LBA8）；宜联YL201鼻咽癌（LBA43）；科伦sac-TMT肺癌两项（LBA66/67）。 10月26日（周日）：和黄SANOVO中国研究（LBA69）；百利天恒iza-bren肺癌（LBA71）；恒瑞SHR-A2009 HER3 ADC（LBA72）；复宏汉霖ASTRIDE美国桥接；科伦TroFuse-005主席研讨会（LBA11）；君实NEOTORCH围术期NSCLC（LBA64）。这些报告读出的HR、中位PFS/OS、安全性数据，才是最终判断药物价值的硬指标。05 为什么这件事值得关注 29项LBA、5个主席研讨会席位、15个ADC——三个数字放在一起，说明中国创新药在ESMO上的角色已经从"参与者"变成了"主要报告者"。更值得注意的是合作模式。5项主席研讨会里，4项有跨国药企深度参与：阿斯利康（和黄SAFFRON、康诺亚CMG901）、GSK（翰森HS-20093）、默沙东（科伦sac-TMT）、Summit（康方依沃西）。中国原研药的全球权益，通过BD交易进入MNC的全球开发管线，然后以全球III期的形式回到ESMO舞台。这不是简单的"中国药企在ESMO发文章"。中国资产已经成为全球肿瘤临床开发链条的一部分——靶点来自中国发现，全球多中心入组，MNC牵头国际注册，最后在国际顶会读出数据。当然，顶线阳性只是第一步。HR值能不能到0.7以下，OS获益能不能转化为监管批准和临床标准治疗的更替，还要看后续的详细数据和监管反馈。接下来四天，马德里还会读出更多数字。我们会持续跟踪。识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

2026-10-23

·FierceBiotech

Roche pays Zymeworks $55M for trispecific challenger to Amgen’s Imdelltra

Roche is paying Zymeworks $55 million upfront for ZW209, bagging global rights to a trispecific designed to improve on the rate and depth of responses achieved by Amgen’s Imdelltra. ZW209 engages DLL3 on tumor cells while simultaneously binding CD3 and CD28 on T cells. The design is a twist on Imdelltra, a bispecific antibody that targets DLL3 and CD3 to turn the immune system against cancer cells. Amgen won FDA approval for Imdelltra in small cell lung cancer (SCLC) in 2024. Boehringer Ingelheim is moving a rival DLL3xCD3 bispecific through phase 3 development. ZW209 is back in phase 1a, but Roche sees promise in the program. In addition to the upfront fee, the Swiss drugmaker will pay Zymeworks $40 million when ZW209 enters a phase 1b trial. The deal includes up to $718 million in additional development, commercial and sales-based milestones, plus royalties. The argument that ZW209 is differentiated is supported by preclinical data that Zymeworks presented last year. Benchmarking ZW209 against a bispecific T-cell engager, the biotech reported improved T-cell fitness and antitumor activity. The trispecific achieved potent antitumor activity in multiple humanized SCLC xenograft models. Zymeworks’ preclinical data offered early evidence that the trispecific design may improve outcomes. The biotech identified the low T-cell infiltration and poor T-cell function characteristic of SCLC as a barrier to strong responses to bispecific DLL3 drugs. T cells can become unresponsive when stimulated via CD3. Targeting CD3 and CD28 could mitigate the constraints on antitumor responses. Roche will support early work to validate that hypothesis in humans. Zymeworks will run the phase 1a trial in collaboration with Roche, which will fund the study. Roche will be responsible for all work beyond the phase 1a trial. SCLC is a focus for Roche, which sells Tecentriq in the tumor type and is developing an antibody-drug conjugate with MediLink. ZW209 is a test case for Zymeworks’ broader ambitions to improve on bispecific T-cell engagers. The drug candidate emerged from discussions about the functionality Zymeworks could add using the extra arm of a trispecific, Zymeworks CEO Kenneth Galbraith said at a Morgan Stanley event last month. Zymeworks picked DLL3 as the first target in the belief it can “provide something extra” over Imdelltra, the CEO said. If ZW209 validates the approach, the biotech has many different targets it can apply the model to across a range of therapeutic areas, Galbraith added.

2026-10-23

·细胞基因治疗前沿

罗氏！2026Q3业绩超预期，砍掉一款CAR-T

▲11月19-20日大湾区创新药产业生态大会免费扫码报名机会注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。 10月22日，罗氏发布2026年前三季度财报。集团销售额464.93亿瑞郎（约合563亿美元），按固定汇率（CER）增长6%，但按瑞郎口径仅增长1%——瑞郎对美元等主要货币的升值吃掉了大部分增幅。第三季度情况有所反转，单季销售额161.3亿瑞郎（约合195亿美元），CER增长7%、瑞郎口径增长8%，增速较上半年明显加快。制药部门前三季度收入362.12亿瑞郎，CER增长7%；诊断部门102.81亿瑞郎，增长4%。公司确认全年指引不变。从治疗领域看，血液板块前三季度71亿瑞郎、增长17%，是增速最高的板块；神经板块76亿瑞郎、增长10%。 Hemlibra（血友病A）37亿瑞郎、增长12%，继续扩大预防治疗的渗透； Polivy 13亿瑞郎、增长24%，一线弥漫大B细胞淋巴瘤适应症放量明显； Lunsumio（莫妥珠单抗）2.06亿瑞郎、增长187%，基数虽小但曲线陡峭； Gazyva也有7.51亿瑞郎、增长7%。罗氏四款双抗产品——Hemlibra、Vabysmo、Columvi、Lunsumio——前三季度合计74.79亿瑞郎，已经成为制药业务里体量最大的产品集群。神经领域的主力仍是Ocrevus，53亿瑞郎、增长7%。这罗氏10月还拿到fenebrutinib在复发型和原发进展型多发性硬化上的FDA优先审评资格，如果获批，神经板块将再添一个口服选项。眼科板块33亿瑞郎、增长9%，几乎全部由Vabysmo贡献——这款双抗前三季度32亿瑞郎、增长10%，在全球眼底病市场持续抢份额。肿瘤板块112亿瑞郎、增长1%，是五大板块里最弱的一环。Herceptin下滑12%至6.95亿瑞郎、Avastin下滑12%至6.39亿瑞郎、Kadcyla下滑9%至13亿瑞郎，三款老产品合计拖累明显。撑住场面的是Tecentriq（26亿瑞郎、+5%）和Alecensa（12亿瑞郎、+6%）。罗氏两款ADC——Kadcyla和Polivy——前三季度合计26.41亿瑞郎，规模上已经被双抗阵营远远甩开。免疫板块50亿瑞郎、增长4%，增速被Actemra的生物类似药竞争压住——这款IL-6R单抗前三季度16亿瑞郎、下滑10%，欧洲市场是重灾区。罗氏在罕见病领域的布局值得单独看。Evrysdi（SMA）前三季度15亿瑞郎、增长18%，这款口服剪接修饰剂已经在与基因疗法和鞘内注射药物的竞争中站稳位置。与财报同步，罗氏做了一次幅度不小的管线梳理：推进13个项目（含3项注册申请），同时剔除13个项目。这13款被剔除的管线中，有一款CD19×CD20异体（allogeneic）CAR-T（RG6540），原本瞄准血液肿瘤。RG6540正是2024年那笔15亿美元Poseida收购案中，被专门点名的两款临床阶段疗法之一。虽然被剔除，但罗氏CEO Thomas Schinecker称没有改变对那笔收购的看法。一边砍掉当初最被看好的资产，一边坚称战略没变。这个矛盾，恰好是罗氏在细胞基因治疗（CGT）上处境的缩影。这家靠小分子和抗体起家的巨头，在CGT上砸了两笔大钱，却始终没能复制它在肿瘤和免疫领域的统治力。罗氏砍掉RG6540，但保留了同平台的RG6538（多发性骨髓瘤），也在继续推进自免方向的细胞治疗。今年上半年，罗氏还砍掉了CD19×CD3双抗RG6382（SLE I期）和亨廷顿病项目tominersen，但制药CEO Teresa Graham当时就明确表态"继续开发自免细胞治疗"。砍的是具体分子，不是整条技术路线。换句话说，罗氏做的是"减法"——把资源从确定性不高的资产里抽出来，集中到少数方向。这符合它今年反复强调的"管线瘦身"逻辑。资料来源：公司官网扫码进群掌握CAR-T疗法、干细胞疗法、基因疗法、溶瘤病毒、核酸药物全方位信息

财报免疫疗法抗体药物偶联物细胞疗法生物类似药

100 项与阿替利珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10773	阿替利珠单抗	L01FF05	DB11595

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
错配修复缺陷或微高卫星不稳定性结肠癌	美国	Genentech, Inc.	2026-10-08
结外NK-T细胞淋巴瘤	日本	Chugai Pharmaceutical Co., Ltd.	2025-09-19
晚期非小细胞肺癌	欧盟	Roche Registration GmbH	2024-07-25
晚期非小细胞肺癌	冰岛	Roche Registration GmbH	2024-07-25
晚期非小细胞肺癌	列支敦士登	Roche Registration GmbH	2024-07-25
晚期非小细胞肺癌	挪威	Roche Registration GmbH	2024-07-25
乳腺癌	加拿大	F. Hoffmann-La Roche Ltd.	2024-03-13
肺泡软组织肉瘤	美国	Genentech, Inc.	2022-12-09
PD-L1阳性非小细胞肺癌	日本	Chugai Pharmaceutical Co., Ltd.	2022-05-26
BRAF V600 突变阳性黑色素瘤	美国	Genentech, Inc.	2020-07-30
PD-L1阳性三阴性乳腺癌	日本	Chugai Pharmaceutical Co., Ltd.	2018-01-19
晚期肝细胞癌	欧盟	Roche Registration GmbH	2017-09-20
晚期肝细胞癌	冰岛	Roche Registration GmbH	2017-09-20
晚期肝细胞癌	列支敦士登	Roche Registration GmbH	2017-09-20
晚期肝细胞癌	挪威	Roche Registration GmbH	2017-09-20
晚期三阴性乳腺癌	欧盟	Roche Registration GmbH	2017-09-20
晚期三阴性乳腺癌	冰岛	Roche Registration GmbH	2017-09-20
晚期三阴性乳腺癌	列支敦士登	Roche Registration GmbH	2017-09-20
晚期三阴性乳腺癌	挪威	Roche Registration GmbH	2017-09-20
广泛期小细胞肺癌	欧盟	Roche Registration GmbH	2017-09-20

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肌层浸润性膀胱癌	申请上市	日本	Chugai Pharmaceutical Co., Ltd.	2026-01-28
膀胱癌	申请上市	中国	Roche Holding AG	2019-02-25
淋巴组织增生性疾病	临床3期	英国	Hoffmann-La Roche Ltd.	2023-10-25
黑色素瘤	临床3期	英国	Hoffmann-La Roche Ltd.	2023-10-25
MSI-H 癌症	临床3期	英国	Hoffmann-La Roche Ltd.	2023-10-25
Turcot综合征	临床3期	英国	Hoffmann-La Roche Ltd.	2023-10-25
局部晚期乳腺癌	临床3期	美国	Roche Diagnostics GmbH	2021-03-29
局部晚期乳腺癌	临床3期	美国	罗氏（中国）投资有限公司	2021-03-29
局部晚期乳腺癌	临床3期	美国	F. Hoffmann-La Roche Ltd.	2021-03-29
局部晚期乳腺癌	临床3期	澳大利亚	罗氏（中国）投资有限公司	2021-03-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05340309 (Pubmed \| Lung Cancer Manag)	临床2期	非小细胞肺癌	5	Atezolizumab SC	遞鹽艱衊窪簾鹹糧艱鬱(憲簾醖積顧憲夢餘餘糧) = 鹹簾餘鏇選築膚鹹醖網齋簾廠夢鬱積範糧齋顧 (艱網艱構餘蓋築顧獵網 ) 更多	积极	2026-12-31
NCT05411081 (SWOG S2200, ESMO2026)	临床2期	乳状状肾细胞癌	33	Cabozantinib 60 mg oral daily	糧簾選鏇鬱憲醖製範壓(簾餘願夢簾壓選淵鬱顧): HR = 0.46 (90.0% CI, 0.22 ~ 0.97), P-Value = 0.043 更多	积极	2026-10-23
				Cabozantinib 60 mg oral daily+ Atezolizumab 1200 mg IV every 3 weeks
ESMO2026	N/A	广泛期小细胞肺癌	851	carboplatin+etoposide+atezolizumab (Asian patients)	製齋鏇網鹹齋範顧鹹窪(製艱築齋鑰製醖鏇淵願) = 範構淵鏇糧簾鹹淵淵襯壓觸蓋醖獵簾廠鹽範顧 (築憲獵壓築窪獵構艱鏇, 65.7 ~ 75.6)	积极	2026-10-23
				carboplatin+etoposide+atezolizumab (White patients)	製齋鏇網鹹齋範顧鹹窪(製艱築齋鑰製醖鏇淵願) = 餘積壓夢鬱餘廠艱願膚壓觸蓋醖獵簾廠鹽範顧 (築憲獵壓築窪獵構艱鏇, 54.9 ~ 77.5)
NCT02693535 (IMvigor210, ESMO2026)	临床2期	局部晚期膀胱癌 TmS	101	Atezolizumab	廠壓構鹹願醖夢構遞鏇(餘遞遞廠衊憲範衊積顧) = 淵鏇繭顧觸淵艱糧構蓋壓窪鏇壓鑰遞壓觸鹽襯 (壓網簾鏇艱顧選觸遞製 )	积极	2026-10-23
				Atezolizumab (TmS-low)	廠壓構鹹願醖夢構遞鏇(餘遞遞廠衊憲範衊積顧) = 齋願繭夢鑰醖簾窪鏇鬱壓窪鏇壓鑰遞壓觸鹽襯 (壓網簾鏇艱顧選觸遞製 )
ESMO2026	N/A	不可切除的肝细胞癌一线	121	Atezolizumab plus bevacizumab with TACE	襯獵淵壓襯簾餘鏇憲糧(醖獵獵膚夢構膚範鹽築) = 窪鑰範鹽鬱憲遞膚網醖壓膚糧醖蓋壓製願襯鹹 (觸範鹽膚憲製膚簾膚繭 ) 更多	积极	2026-10-23
				Atezolizumab plus bevacizumab without TACE	襯獵淵壓襯簾餘鏇憲糧(醖獵獵膚夢構膚範鹽築) = 鑰觸積選願選製齋製網壓膚糧醖蓋壓製願襯鹹 (觸範鹽膚憲製膚簾膚繭 ) 更多
ESMO2026	N/A	转移性非小细胞肺癌一线 PD-L1 ≥ 50%	411	Pembrolizumab	網構築製選衊製鹹襯蓋(鑰窪鑰製鹹簾憲衊蓋獵) = 鬱憲廠鏇壓繭壓餘製壓憲齋醖繭壓夢艱範膚願 (遞齋糧鑰膚鹹獵膚艱襯 ) 更多	积极	2026-10-23
				Atezolizumab	網構築製選衊製鹹襯蓋(鑰窪鑰製鹹簾憲衊蓋獵) = 顧醖衊夢選鹽壓鬱壓築憲齋醖繭壓夢艱範膚願 (遞齋糧鑰膚鹹獵膚艱襯 ) 更多
NCT03697850 (GETUG-35, ESMO2026)	临床2期	肌层浸润性膀胱癌维持	78	Maintenance atezolizumab	獵選廠顧鏇築築膚壓糧(製襯窪壓襯觸夢網夢觸) = 繭製窪衊廠鏇簾窪窪齋艱淵醖觸壓鹽遞鏇餘鑰 (鑰淵鑰壓膚衊網製獵蓋, 62.2 ~ 82.4) 更多	积极	2026-10-23
NCT06049966 (LANCE, ESMO2026)	临床2期	大细胞神经内分泌肺癌一线 miR-375	41	carboplatin+ etoposide+atezolizumab	窪鏇壓獵構鏇壓繭繭遞(憲廠鹹簾襯窪襯膚淵膚) = 衊製鬱憲鏇網壓壓鬱製憲遞齋齋簾醖繭簾衊艱 (願鬱築淵顧鑰襯醖選獵 ) 更多	积极	2026-10-23
ESMO2026	N/A	转移性结直肠癌 PD-L1	3,799	Atezolizumab containing regimens	製淵夢鏇範鏇壓廠蓋夢(蓋鬱遞選夢築夢築願醖): RR = 1.42 (95.0% CI, 1.04 ~ 1.94), P-Value = 0.026 更多	不佳	2026-10-23
				Non-atezolizumab standard therapy
NCT02912559 (ATOMIC, ESMO2026)	临床2期	III期结肠癌辅助 d-MMR	712	Atezolizumab+chemo (EOCC)	衊鏇膚鹽製鑰艱窪艱鏇(鹹齋顧鹹獵積廠蓋糧壓) = In the atezo+chemo arm, grade 3 and 4 AEs of diarrhea, hypokalemia, neutropenia and lymphopenia were higher in AOCC vs EOCC pts. No meaningful AE differences were seen in the chemo-only arm. 簾網鏇鹹餘範糧願觸夢 (鏇範夢積鏇廠願窪獵襯 ) 更多	积极	2026-10-23
				Atezolizumab+chemo (AOCC)